Sable Therapeutics has announced that it will enter into a licensing agreement with Liuqiang Medical Technology Co. The deal will give Liuqiang exclusive rights to develop and commercialize Sable Therapeutics’ SBL-003/SBL-004 microneedle patch incorporating a fat “browning” patch for targeted aesthetic fat reduction purposes in Greater China. In exchange for this, Liuqiang will make an undisclosed upfront payment to Sable Therapeutics. Sable Therapeutics will benefit from Liuqiang Medical Technology’s formulation, development, and manufacturing expertise as it looks to commercialize the technology outside of Greater China.
Sable Therapeutics, an early stage biotechnology company developing novel therapies for fat reduction, today announced that it will enter into a licensing agreement with Liuqiang Medical Technology Co. In exchange for an undisclosed upfront payment, Liuqiang will acquire exclusive rights to develop and commercialize Sable Therapeutics’ microneedle patch incorporating SBL-003 and SBL-004 in Greater China. Sable Therapeutics’ SBL-003/SBL-004 microneedle patch is a fat “browning” patch that is used for targeted aesthetic fat reduction purposes.
Additionally, Sable Therapeutics will benefit from Liuqiang Medical Technology’s formulation, development and manufacturing expertise as it looks to commercialize the technology in all regions outside of Greater China. “We are thrilled to announce this partnership with Liuqiang Medical Technology. They are a leading company with deep expertise in microneedle patch research and development across a variety of targeted indications,” said Dr. Li Qiang, Scientific Co-Founder and Associate Professor of Pathology and Cell Biology at Columbia University Medical Center.
“This exciting agreement will help drive and accelerate our own internal efforts as we look to introduce our novel fat burning microneedle patch technology into the large global aesthetics marketplace,” said Daniel Chai, M.D., Managing Partner of Turret Capital and Co-Founder and Acting Chief Executive Officer of Sable Therapeutics.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: BioSpace